← 21 Aug 2026 · Short-term Top 10 — Health Care
Short-term Top 10 — Health Care — what changed on 24 Aug 2026
A dated record of one session: what entered or left, what moved inside the ten and by how much, who is closest to the boundary, and how the list did against its benchmark. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100.
The short-term score is a published weighted sum of percentile ranks, rebalanced every Monday. A list is a published formula and its output, not a recommendation. Method version 3.
Get this list's changes by email
Who entered, who left, and the reason — with the score moves behind it.
Informational only — not financial advice. The daily email has not started yet — subscribing now puts you on the list for the first one. Unsubscribe in one click.
Membership changes on 24 Aug 2026
Entered
- GLAUKOS CORP (GKOS) (rank 0 → 4)
Entered 24 Aug 2026: score 70.2, rank 4 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version). - KINIKSA PHARMACEUTICALS INTERNATIO (KNSA) (rank 0 → 8)
Entered 24 Aug 2026: score 66.4, rank 8 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version). - Merck & Co. (MRK) (rank 0 → 1)
Entered 24 Aug 2026: score 72.1, rank 1 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version). - Moderna (MRNA) (rank 0 → 9)
Entered 24 Aug 2026: score 66.0, rank 9 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version). - NUVATION BIO INC CLASS A (NUVB) (rank 0 → 10)
Entered 24 Aug 2026: score 66.0, rank 10 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version). - Revolution Medicines (RVMD) (rank 0 → 7)
Entered 24 Aug 2026: score 68.2, rank 7 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version). - ZENAS BIOPHARMA INC (ZBIO) (rank 0 → 3)
Entered 24 Aug 2026: score 71.3, rank 3 (vs 18 Aug 2026).
Left
- Agilent Technologies (A) (rank 0 → 30)
Left 24 Aug 2026: score 62.5, rank 30 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15). - BridgeBio Pharma, Inc. (BBIO) (rank 0 → 105)
Left 24 Aug 2026: score 52.9, rank 105 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15). - CELLDEX THERAPEUTICS INC (CLDX) (rank 0 → 86)
Left 24 Aug 2026: score 55.5, rank 86 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15). - Encompass Health (EHC) (rank 0 → 49)
Left 24 Aug 2026: score 58.5, rank 49 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15). - EDGEWISE THERAPEUTICS INC (EWTX) (rank 0 → 17)
Left 24 Aug 2026: score 64.3, rank 17 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15). - MINIMED INC (MMED) (rank 0 → 38)
Left 24 Aug 2026: score 61.3, rank 38 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15). - Veeva Systems (VEEV) (rank 0 → 28)
Left 24 Aug 2026: score 62.7, rank 28 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
Inside the ten
Not compared with the previous session, 21 Aug 2026: those rows were scored under method version 2 and this session under version 3, and the formula changed between them, so a score is only comparable within one version.
| Company | Rank | Score | Pillar that moved most |
|---|---|---|---|
| Merck & Co. (MRK) | 1 | 72.1 0.0 | no pillar moved materially |
| HINGE HEALTH INC CLASS A (HNGE) | 2 | 71.6 0.0 | no pillar moved materially |
| ZENAS BIOPHARMA INC (ZBIO) | 3 | 71.3 0.0 | no pillar moved materially |
| GLAUKOS CORP (GKOS) | 4 | 70.2 0.0 | no pillar moved materially |
| IMMUNOME INC (IMNM) | 5 | 69.6 0.0 | no pillar moved materially |
| DEFINIUM THERAPEUTICS INC (DFTX) | 6 | 69.5 0.0 | no pillar moved materially |
| Revolution Medicines (RVMD) | 7 | 68.2 0.0 | no pillar moved materially |
| KINIKSA PHARMACEUTICALS INTERNATIO (KNSA) | 8 | 66.4 0.0 | no pillar moved materially |
| Moderna (MRNA) | 9 | 66.0 0.0 | no pillar moved materially |
| NUVATION BIO INC CLASS A (NUVB) | 10 | 66.0 0.0 | no pillar moved materially |
At the edge
Knocking
- NURIX THERAPEUTICS INC (NRIX) 0.2 below the lowest member
- Baxter International (BAX) 0.7 below the lowest member
Closest to the exit
- KINIKSA PHARMACEUTICALS INTERNATIO (KNSA) 1.8 above the score at rank 15, where the hold band ends
- Moderna (MRNA) 1.4 above the score at rank 15, where the hold band ends
- NUVATION BIO INC CLASS A (NUVB) 1.4 above the score at rank 15, where the hold band ends
Ranked against 236 eligible Health Care companies on this session. A company at the edge is a company near a boundary, not a prediction that it will cross one.
Against the benchmark
SPY is the S&P 500 ETF — the US large-cap market average.
−0.8% since the previous session (2026-08-21), against −0.3% for SPY — 0.5 points behind the benchmark. Tracked since 2026-08-18.
+0.1% since 2026-08-18, against −0.5% for SPY — 0.6 points ahead of the benchmark. Tracked since 2026-08-18.
Both curves are total return through 24 Aug 2026: a distribution buys more of the company that paid it, on the benchmark as much as on the list.
More
Informational only — NOT financial advice.